Search

Chitosan oligosaccharides are biopolymers with a wide range of potential applications in various fields. This biopolymer is diverse and promising, and current research is investigating its capabilities for improved drug delivery. As chitosan oligosaccharide has the potential to be used as a drug delivery option, the purpose of this study was to examine its physicochemical characteristics and its potential for drug delivery. In this study, the pharmacokinetic properties of chitosan oligosaccharide were studied through Insilco investigation, which revealed that it is an extremely soluble and effective drug delivery candidate because it does not inhibit CYP isoenzymes and has a log Kp of −12.10 cm/s. It belongs to toxicity class 6 for acute oral toxicity, with an average similarity of 87.5% and a prediction accuracy of 70.97%. Additionally, XRD peak analysis revealed that the material was amorphous, as the peak appeared at 2θ = 24.62°, indicating the absence of well-defined crystalline areas. This characteristic makes the material more suitable for customization in many applications such as drug delivery and tissue engineering. FTIR, SEM, and TGA analysis were performed to gain a better understanding. These findings also emphasize the distinctive qualities and benefits of the oligosaccharides in this domain. Application of chitosan oligosaccharides in the development of efficient drug delivery systems. In the future, it would be more effective, targeted, and safe, with potent therapeutic efficacy for drug delivery. [ABSTRACT FROM AUTHOR]

ABSTRACT Epithelial ovarian cancer (EOC) has the highest mortality rate among malignant tumors of the female reproductive system and the lowest survival rate. This poor prognosis is due to the aggressive nature of EOC, its late‐stage diagnosis, and the tumor's ability to adapt to stressors through metabolic reprogramming. EOC cells sustain their rapid proliferation by altering the uptake, utilization, and regulation of carbohydrates, lipids, and amino acids. These metabolic changes support tumor growth and contribute to metastasis, chemotherapy resistance, and immune evasion. Targeting these metabolic vulnerabilities has shown promise in preclinical studies, with some therapies advancing to clinical trials. However, challenges remain due to tumor heterogeneity, adaptive resistance mechanisms, and the influence of the tumor microenvironment. This review provides a comprehensive summary of metabolic targets for EOC treatment and offers an overview of the current landscape of clinical trials focusing on ovarian cancer metabolism. Future efforts should prioritize combination therapies that integrate metabolic inhibitors with immunotherapies or chemotherapy. Advances in precision medicine and multi‐omics approaches will be crucial for identifying patient‐specific metabolic dependencies and improving outcomes. By addressing these challenges, metabolism‐based therapies can significantly transform the treatment of this devastating disease. [ABSTRACT FROM AUTHOR]

Metal compounds with S = 1/2 coordination-frameworks have been emerging as new powerful qubit candidates. In this study, we have reported the CN-based coordination framework TMA2[KCo1−xFex(CN)6] to be a qubit. We explored the magnetization dynamics and spin coherence of the magnetic dilution of the S = 1/2 Fe(III) complex TMA2[KFe(CN)6] (TMA = tetramethylammonium) in its Co(III)-based diamagnetic analogue TMA2[KCo(CN)6]. Alternating-current (AC) susceptibility data illustrate a slow magnetic relaxation upon applying a field of 0.1 T, which follows the phonon-bottleneck relaxation mechanism along with the Raman process. A magnetic relaxation time (τ) of 0.3 s (2% Fe) was realized at 1.8 K. Moreover, pulsed EPR data reveal a coherence duration of 1 μs (0.1% Fe) at 4 K with successful observation of Rabi oscillation at 4 K and 13 K (2% Fe) using MW pulses with variable irradiation-field strengths. The overall results indicate that TMA2[KCo1−xFex(CN)6] represents a promising qubit candidate, as it is capable of being placed in any superposition of the two distinct Ms states (Ms = +1/2 and Ms = −1/2). [ABSTRACT FROM AUTHOR]

With the aim of creating Cu(II) spin qubits in a rigid metal–organic framework (MOF), this work demonstrates a doping of 5 %, 2 %, 1 %, and 0.1 % mol of Cu(II) ions into a perovskite‐type MOF [CH6N3][ZnII(HCOO)3]. The presence of dopant Cu(II) sites are confirmed with anisotropic g‐factors (gx=2.07, gy=2.12, and gz=2.44) in the S=1/2 system by experimentally and theoretically. Magnetic dynamics indicate the occurrence of a slow magnetic relaxation via the direct and Raman processes under an applied field, with a relaxation time (τ) of 3.5 ms (5 % Cu), 9.2 ms (2 % Cu), and 15 ms (1 % Cu) at 1.8 K. Furthermore, pulse‐ESR spectroscopy reveals spin qubit properties with a spin‐spin relaxation (phase memory) time (T2) of 0.21 μs (2 %Cu), 0.39 μs (1 %Cu), and 3.0 μs (0.1 %Cu) at 10 K as well as Rabi oscillation between MS=±1/2 spin sublevels. T2 above microsecond is achieved for the first time in the Cu(II)‐doped MOFs. It can be observed at submicrosecond around 50 K. These spin relaxations are very sensitive to the magnetic dipole interactions relating with cross‐relaxation between the Cu(II) sites and can be tuned by adjusting the dopant concentration. [ABSTRACT FROM AUTHOR]